Emma Cacciola, Ernesto Di Francesco, Francesca Pezzella, Daniele Tibullo, Rossella Cacciola
{"title":"阿那格列特对原发性血小板增多症患者JAK2突变状态的影响","authors":"Emma Cacciola, Ernesto Di Francesco, Francesca Pezzella, Daniele Tibullo, Rossella Cacciola","doi":"10.3816/CLK.2008.n.038","DOIUrl":null,"url":null,"abstract":"<div><p>We evaluated the effect of anagrelide (ANA) in 9 of 22 patients with essential thrombocythemia (ET) who had a JAK2 V617F mutation and polycythemia vera (PV)–like disease. First, we observed a successful reduction of JAK2 mutation, which was associated with disappearance of PV-like phenotype. Second, we found that a level of JAK2 mutation < 50% was associated with a response to ANA similar to that of JAK2-negative patients. These data indicate that ANA may reverse the JAK2 mutational status and provide a better prognosis in patients with ET.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"2 4","pages":"Pages 272-274"},"PeriodicalIF":0.0000,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2008.n.038","citationCount":"4","resultStr":"{\"title\":\"Effect of Anagrelide on JAK2 Mutational Status in Patients with Essential Thrombocythemia\",\"authors\":\"Emma Cacciola, Ernesto Di Francesco, Francesca Pezzella, Daniele Tibullo, Rossella Cacciola\",\"doi\":\"10.3816/CLK.2008.n.038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We evaluated the effect of anagrelide (ANA) in 9 of 22 patients with essential thrombocythemia (ET) who had a JAK2 V617F mutation and polycythemia vera (PV)–like disease. First, we observed a successful reduction of JAK2 mutation, which was associated with disappearance of PV-like phenotype. Second, we found that a level of JAK2 mutation < 50% was associated with a response to ANA similar to that of JAK2-negative patients. These data indicate that ANA may reverse the JAK2 mutational status and provide a better prognosis in patients with ET.</p></div>\",\"PeriodicalId\":100271,\"journal\":{\"name\":\"Clinical Leukemia\",\"volume\":\"2 4\",\"pages\":\"Pages 272-274\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3816/CLK.2008.n.038\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1931692513600443\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1931692513600443","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effect of Anagrelide on JAK2 Mutational Status in Patients with Essential Thrombocythemia
We evaluated the effect of anagrelide (ANA) in 9 of 22 patients with essential thrombocythemia (ET) who had a JAK2 V617F mutation and polycythemia vera (PV)–like disease. First, we observed a successful reduction of JAK2 mutation, which was associated with disappearance of PV-like phenotype. Second, we found that a level of JAK2 mutation < 50% was associated with a response to ANA similar to that of JAK2-negative patients. These data indicate that ANA may reverse the JAK2 mutational status and provide a better prognosis in patients with ET.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
